Alternatives to SpliceCore

Our AI engine transforms drug discovery. Our discoveries help create better medicines faster. Our AI-enabled discovery portfolio is co-owned and owned by prominent investors. Atomwise developed a machine-learning-based discovery engine that combines the power of convolutional neural networks with massive chemical libraries to discover new small-molecule medicines. People are the key to redefining drug discovery using AI. We are committed to creating the best AI platform possible and using it to transform small-molecule drug discovery. To help drug developers achieve their goals, we have to tackle the most difficult and seemingly impossible targets. We also need to streamline the drug discovery process in order to make it more efficient. The ability to screen trillions of compounds in silica increases the chance of success. Demonstrates exceptional model accuracy, surpassing the challenge of false negatives.

SYNTHIA™ Retrosynthesis software, developed by computer scientists and coded by chemists, allows scientists to quickly and easily navigate novel and innovative pathways for novel and previously published target molecules. You can quickly and efficiently scan hundreds pathways to identify the best options for your needs. Discover the most cost-effective route to your target molecule with the latest visualization and filtering features. You can easily customize the search parameters to eliminate or highlight reactions, reagents, or classes of molecules. Explore innovative and unique syntheses to build your desired molecule. Easy to generate a list for starting materials that are commercially available for your synthesis. ISO/IEC 27001 Information Security Certification will guarantee the confidentiality, integrity and protection of your data.

We are a biotechnology company in clinical stage. We decode biology by integrating technological innovations across biology and chemistry to industrialize drug discovery. CRISPR genome editing and synthetic Biology allow for greater control over biology. Advanced robotics allows for reliable automation of complex laboratory research on an unprecedented scale. Neural network architectures allow for iterative analysis and inference from large, complex, in-house data sets. Cloud solutions increase the flexibility of high-performance computation. To build a next-generation biopharmaceutical business, we are using new technology to create virtuous learning cycles around datasets. A synchronized combination hardware, software, and data that is used to industrialize drug discovery. Redefining the traditional drug discovery process. One of the most extensive, broadest, and deepest pipelines in any technology-enabled drug company.

BIOiSIMTM, a revolutionary 'virtual drug engine', is the first-in-class tool that allows drug developers to narrow down the number drugs that have potential value in treating or curing specific diseases or illnesses. We offer a variety of translational-based solutions that can be customized for your clinical and pre-clinical programs. All of these solutions are based on our BIOiSIMTM platform, which is a proven and validated platform for small molecules, large molecule, and viruses. Our models are built using data from thousands upon thousands of compounds across seven species, which gives them a robustness that is rare in the industry. The platform is focused on human outcomes and has at its core a translatability tool that transforms insights across species. The BIOiSIMTM platform is available before preclinical animal trials begin, which allows for earlier insights and saves on expensive outsourced experimentation.

Genedata Biologics®, streamlines the discovery of biotherapeutics. This includes bispecifics and ADCs as well as TCRs, CARs-Ts, CARs-Ts, CARs, and AAVs. It integrates all discovery workflows, making it the most popular platform in the industry. This allows you to focus on innovation and is the most widely used. A first-in-class platform that digitalizes biotherapeutic discovery accelerates research. The platform simplifies complex R&D processes by allowing for the creation, tracking, testing, and evaluation of novel biotherapeutics drugs. It can work with any format: antibodies, bi- and multi-specifics as well as ADCs, novel scaffolds, therapeutic proteins, and engineered therapeutic cell line such CAR-T cells and TCRs. Genedata Biologics acts as a central data backbone that integrates all R&D processes. This includes library design, immunizations, selections, panning, molecular Biology, screening, protein engineering and expression, as well as candidate development and manufacturability assessment.

BioNeMo, an AI-powered cloud service for drug discovery and framework, is built on NVIDIA NeMo Megatron. It is used to train and deploy large biomolecular Transformer AI models at supercomputing scale. The service provides pre-trained large language models (LLMs), native support for common file types for proteins, DNA, and chemistry, as well as data loaders for SMILES molecular structures and FASTA amino acid and nucleotide sequencings. You can also download the BioNeMo framework to run on your own infrastructure. ESM-1, which is based on Meta AI’s state-of the-art ESM-1b and ProtT5 respectively, are transformer-based protein-language models that can be used for learning embeddings for tasks such as property prediction and protein structure. BioNeMo will offer OpenFold, a deep-learning model for 3D structure prediction and novel protein sequences.

InSilicoTrials.com, a web-based platform that allows users to create and simulate computational models and simulations. There are many easy-to-use tools in silico. The platform is primarily for users in the medical device and pharmaceutical industries. In silico tools for medical devices allow computational testing in different biomedical areas such as radiology, orthopedics, and cardiovascular during product development, validation, and design. The platform offers access to in-silico tools for the pharmaceutical industry, which can be used at all stages of drug discovery and development. It also covers a variety of therapeutic areas. The only cloud-platform built on crowdscience makes it easy to access validated models and reduce your R&D expenses. There is a growing list of models that can be used on a pay-per-use basis.

Clara's domain specific tools, AI pretrained models, accelerated applications, and accelerated AI applications are enabling AI advances in many fields, including medical device, imaging, drug discovery and genomics. Holoscan allows you to explore the entire pipeline of medical device deployment and development. With the NVIDIA IGX Developer Kits, you can build containerized AI apps using the Holoscan SDK. The NVIDIA IGX SDK includes pre-trained AI model, healthcare-specific acceleration libraries and reference applications for medical devices.

The process of bringing a new drug to market, from the initial step to the final market introduction can be time-consuming, expensive, and highly regulated. It can take up to a decade. Final success depends on early access to accurate analytical results that are fast enough to make the right decisions during development and minimize late attrition. Today's drug development relies heavily on a rational approach. Typically, identifying the biological target is the first step. To identify the most promising candidates, it is necessary to have a deep understanding about their properties. Finding the most promising lead molecules can be a daunting task once a biological target is established. Lead discovery is typically the identification of potential drug candidates, either small organic molecules or biologic assembly with therapeutic potential.

LiveDesign is an enterprise information platform that allows teams to collaborate, design, experiment, analyze, track, and report in one central platform. You can capture ideas and model data. Create and store virtual compounds in a central database. Use advanced models to prioritize new designs. Integrate biological data and model results from federated corporate databases. Use sophisticated cheminformatics for faster analysis and development of compounds. Advanced physics-based methods are combined with machine learning techniques to quickly improve prediction accuracy. Remote team members can collaborate in real-time. You can collaborate with remote team members to share ideas, test, revise, or advance chemical series without losing sight of your work.

AIDDISON™, a drug discovery software, combines the power and efficiency of artificial intelligence (AI), computer-aided design (CADD), and machine learning (ML) to provide a valuable toolkit that can be used for medicinal chemistry. It is a unified platform that integrates all aspects of virtual screening, including ligand-based design and structure-based design. It also supports methods for in silico lead optimization and discovery.

Advanced molecular modeling can transform drug discovery and materials research. Our physics-based computational platform combines differentiated solutions for predictive modelling, data analytics, collaboration, and collaboration to allow rapid exploration of chemical space. Our platform is used by industry leaders around the world for drug discovery and materials science in fields such as aerospace, energy, semiconductors and electronics displays. The platform powers our drug discovery efforts, from target identification through hit discovery to lead optimization. It also powers our research collaborations to create novel medicines for critical public healthcare needs. Our team includes more than 150 Ph.D. scientists. This allows us to invest heavily in R&D.

Use AI to accelerate the journey from bench-research and laboratory insights to life-changing therapies. Reduce your reading time to minutes and gain up to 90% more research productivity. With a high-precision and high-accuracy research, you can cut through the noise to navigate the ever-growing amount of scientific literature. Save time, reduce bias, and increase the odds of discovering novel things. Explore disease biology in depth and discover advanced targets. Causaly’s high-precision graph of knowledge consolidates evidence from millions publications, allowing for unbiased, deep scientific exploration. You can navigate cause-and effect relationships in biology without being an expert. Discover hidden connections by viewing all scientific documents. Causaly’s powerful AI machine is able to read millions of published biomedical publications in order to support better research and decision-making.

Kanteron Platform ingested digital pathology slides, medical images, and patient data from modalities and sequencers. It then provided a complete data toolkit for all hospital network teams. Precision Medicine at the point-of-care: Pharmacogenomics is used to prevent adverse medication events. It also incorporates data sources that have drug-gene interactions that were not previously available in easily accessible formats (e.g. Tables in a PDF document) and implementing the major Pharmacogenomic Databases (like PharmGKB or DGIdb, OpenTargets ...). This allows the user to refine their query to specific gene families, types, interactions, etc. Flexible AI allows you to choose the data set that is most appropriate for your use case and then apply it to your relevant medical images.

Rare diseases are often poorly understood and only a small amount of information is available to support drug discovery programs. Healnet, an AI platform that analyzes millions of data points related to drug and disease, helps overcome these challenges. It identifies novel connections that could lead to new treatment options. We can simultaneously run multiple stages at scale by applying frontier technologies throughout the discovery and development process. It's a simple model that can be used by almost all pharmaceutical companies. One disease, one target and one drug. The next generation in drug discovery is AI-powered and parallel. The key three paradigms of drug discovery are combined.

To drive precision medicine programs that work, pharmaceutical companies require comprehensive genomic information. However, decisions are often made with only 10% of the data available. Genomenon provides 100% of the data. ProdigyTM Patient Landscapes are a cost-effective and efficient natural history research solution for pharmaceuticals. They enhance insights from retrospective and prospective health data to support the development rare disease therapies. Genomenon uses an AI-driven approach to deliver a thorough and expert assessment of all patients in the medical literature in a fraction time. Get a complete overview of every genomic biomarker in the medical literature. Every scientific assertion is supported with empirical evidence from medical literature. Identify all genetic drivers and determine which variants are pathogenic according ACMG clinical standards.

3decision®, a cloud-based repository of protein structures, is designed to manage structural data and perform advanced analytics. This allows small molecule and biologicals discovery teams the ability to accelerate structure-based drugs design. It centralizes, standardizes, and integrates experimental and in silico protein structures derived from public sources such as RCSB PDB, AlphaFoldDB as well as proprietary information, including formats like PDBx/mmCIF, and ModelCIF. This allows for easy access to X-Rays, NMRs, cryo-EMs, and modeled protein structures. It also fosters collaboration and enhances research efforts. 3decision®, beyond storage, enriches entries by adding metadata and sequence data, including annotations of antibodies, binding site details, and protein-ligand interaction. Advanced analytical tools can identify druggable site, assess off-target risk, and enable binding sites comparisons. They transform vast structural data into actionable information. Cloud-based platform allows for collaboration between research teams.

StarDrop™, a comprehensive suite of integrated software, delivers the best in silico technology within a highly visual interface. StarDrop™, which allows seamless flow between the latest data, predictive modeling, and decision-making regarding the next round or synthesis, improves the speed, efficiency and productivity of the discovery process. A balance of different properties is essential for successful compounds. StarDrop™, which guides you through the multi-parameter optimization challenge, helps you target compounds with the highest chance of success. It also saves you time and resources by allowing you to synthesize fewer compounds and test them less often.

Amazon Neptune is a fully managed graph database service that allows you to quickly and reliably build applications that can work with highly connected data sets. Amazon Neptune's core is a purpose-built graph database engine that can store billions of relationships and query the graph with only milliseconds latency. Amazon Neptune supports the popular graph models Property Graph, W3C's RDF, as well as their respective query languages Apache TinkerPop Gremlin, SPARQL. This allows you to quickly build queries that efficiently navigate large datasets. Neptune supports graph use cases like recommendation engines, fraud detection and knowledge graphs. It also powers network security and drug discovery.

The biopharmaceutical market is complex today. There are growing demands for better specificity and safety, new treatment classes, and more complex mechanisms of disease. To keep up with this complexity, we need to have a better understanding of therapeutic behavior. Simulation and modeling provide unique opportunities to explore biological and physical processes down to the atomic levels. This can be used to guide physical experimentation and accelerate the discovery and development process. BIOVIA Discovery Studio brings together more than 30 years of peer reviewed research and world-class in-silico techniques like molecular mechanics and free energy calculations. It also allows for biotherapeutics developmentability and other related topics into one environment. It gives researchers a complete toolkit to explore the nuances in protein chemistry and to catalyze the discovery of small and big molecule therapeutics, from Target ID to Lead Optimizement.

Scitara DLX™ provides a fast connectivity infrastructure for any instrument used in life science laboratories. It is fully compliant and auditable, and can be accessed from any cloud-based platform. Scitara™, a universal digital data network, connects all instruments, resources, apps, and software within the laboratory. The cloud-based platform, which is fully auditable, connects all data sources in the lab, allowing data to flow freely across multiple endpoints. Scientists can now spend their time on scientific research and not waste it trying to solve data problems. DLX corrects and curates flight data to support the creation of precise, structured data models that feed AI/ML systems. This supports a successful digital transformation strategy for the pharma and biopharma sectors. The ability to access scientific data allows for faster decision-making and drug discovery, which helps bring drugs to market quicker.

Eidogen-Sertanty’s Target Informatics platform (TIP), is the first global structural informatics system. It enables researchers to examine the druggable genome from an structural perspective. TIP increases the rapidly expanding body experimental protein structure information and transforms structure based drug discovery from an inefficient, data-scarce discipline to a high-throughput science with rich data. TIP is a tool that bridges the knowledge gap between bioinformatics (bioinformatics) and cheminformatics. It provides drug discovery researchers with a knowledge bank of information that is both unique and highly complementary to existing bio- and cheminformatics platform information. TIP's seamless integration between structural data management technology and unique target-to-lead analysis capabilities enhances every stage of the discovery pipeline.

AI-powered drug discovery is a proven technology. Cerella extracts hidden insights from your drug discovery data to reveal the best compounds and most valuable experiment for your project. It can make confident predictions by accurately filling in the missing values. This is especially useful for expensive downstream experiments, which are impossible to predict using other methods. This allows you to do more with sparse and limited data sets.

Mantarray provides functional data in the early stages of preclinical testing for new medicines. Mantarray allows for parallel analysis of 3D engineered muscles tissues with adult-like functional profiles. This facilitates the discovery, safety and efficacy testing new therapeutics. The Mantarray Plate Kit has a 95% success rate in tissue formation and allows for reproducible engineered tissue production across 24 wells. The Mantarray platform is a flexible, easy-to-use, and scalable system that allows researchers to study 3D tissues in vitro from the comfort of their own laboratory. You will be among the first to receive this instrument. Mantarray's magnetic sensing technology detects the contraction of EMTs. This allows the user to measure the contractility in 24 tissues simultaneously, at a high throughput and in real-time. The software is user-friendly and eliminates the need for manual calculation of contractility.

DNAnexus Apollo™, accelerates precision drug discovery through collaboration that draws critical insights from omics data. Precision drug discovery requires the collection and analysis of large volumes of clinical and omics data. These data sets are extremely rich, but many legacy and home-grown informatics tools cannot handle their complexity and size. Silos, insufficient collaboration tools, and complex regulatory and security requirements can all hinder precision medicine programs. DNAnexus Apollo™, which supports precision drug discovery programs, empowers scientists and clinicians to analyze and explore omics and clinical data in a single environment built on a robust and scalable cloud platform. Apollo allows them to share data, tools and analyses securely with peers and colleagues from all over the world, regardless of whether they are on another floor or another continent.

VeraChem LLC was established in 2000 to advance computer-aided drug discovery. These methods are implemented in high-performance software and provide comprehensive support to users. This is a key strategy of VeraChem LLC for product development. Current VeraChem software capabilities include host-guest and protein-ligand binding affinity prediction, fast calculation and computation of partial atomic charges for druglike compounds, computation and force of energies and forces using all the most commonly used empirical force field, automatic generation and generation of alternate resonance forms for drug-like substances, conformational search using the powerful Tork algorithm and automatic detection and removal of topological and 3D-molecular symmetries. VeraChem's software packages were built from a modular code base.

AutoDock is a set of automated docking tools. It predicts how small molecules, such sub- or drug candidates, will bind to a receptor with a known 3D structure. It has been improved over the years to add new functionalities and multiple engines were developed. AutoDock 4 is the current version, and AutoDock Vina is the latest. AutoDock-GPU is an accelerated version that runs hundreds of times faster than the original single CPU docking code. AutoDock 4 is actually composed of two main programs. Autodock docks the ligand to a list of grids that describe the target protein. Autogrid pre-calculates the grids. The atomic affinity grids can also be visualized. This can be used to help organic synthetic chemists create better binders.

Many diseases and conditions are linked to the microbiome. Discover how Kaleido is transforming the promise of microbiome into solutions that benefit patients. The human microbiome, which includes bacteria, viruses, archaea, fungi and other organisms, is a collection of over 30 trillion microbes. Research has increased exponentially over the past decade on the effects of the microbiome on human health, including diabetes, heart disease, Parkinson's disease, and cancer. This complex microbial ecosystem has been called a "newly discovered" organ. Many other human organs are worth tens to billions of dollars for therapeutics that modify physiology and treat disease. The microbiome organ is a promising therapeutic option.

Altis Labs launches Nota, a clinical information platform that accelerates R&D for therapeutics. AI predicts patient outcomes based on imaging data, so sponsors can prioritize their most promising treatments. Nota allows researchers to access imaging biomarkers and speed up R&D by operationalizing clinical trial imaging data. Altis' cloud software platform powered with deep learning allows biopharma to incorporate comprehensive outcomes predictions at the image level, patient level, and cohort-level in order to improve clinical trial designs and better anticipate clinical endpoints. These insights can accelerate drug development timelines and lower costs, while increasing the likelihood of success in clinical trials across therapeutic areas.

BC platforms uses the latest science, unique technology capabilities and strategic partnerships to accomplish our mission of revolutionizing drug discovery, personalizing care, and transforming medicine. Modular, flexible platform that integrates healthcare data. Open analytics framework seamlessly combines the most innovative methods, technology developments and analytics in one platform. Superior security: ISO 27001 certified and GDPR and HIPAA compliant. A complete product portfolio allows modern healthcare systems to fully embrace personalized medicine. Scalable deployments allow for a robust start and large-scale healthcare operation. Our unique toolbox enables faster translation of research insights into clinical practice. Our unique toolbox helps reduce risk, increase your pipeline value, and advance enterprise data strategy. We remove the barriers to data access and enable rapid insight generation.

NVIDIA®, Parabricks®, is the only GPU accelerated suite of genomic analysis apps that delivers fast, accurate analysis of exomes and genomes for sequencing centres, clinical teams and high-throughput instrument developers. NVIDIA Parabricks provides GPU-accelerated versions of tools used every day by computational biologists and bioinformaticians--enabling significantly faster runtimes, workflow scalability, and lower compute costs. NVIDIA Parabricks can accelerate runtimes in a variety of hardware configurations, from FastQ to Variant Call format (VCF). This is done with NVIDIA Tensor Core GPUs. Genomic researchers will experience acceleration at every step of their analysis workflows - from alignment to sorting and variant calling. The compute time can be accelerated up to 107X when more GPUs are added.

We combine clinical and experimental data with machine learning to improve precision medicine and navigate human disease biology. Contingent AI™, a patent-pending technology, understands data relationships to provide sophisticated insights. We tackle data bias by iterating upon machine learning models that are based on decisions made during the feature engineering and pre-processing stages. We use zebrafish, cell, and other phenotypic animals models to validate in-silico predictions in in vivo experiments. We also genetically modify them in vitro to improve translation. We quickly incorporate new data into machine learning models by using active learning and computer vision on validated models of cardiac, central nervous system, and rare disorders.

Our reputation as thought leaders in the areas of ADMET property prediction, physiologically-based pharmacokinetics (PBPK) modeling, pharmacometrics, and quantitative systems pharmacology/toxicology is earned through the success our clients have found through their relationship with us. With over 20 years of experience, we have the ability to translate science into software that is easy to use. We also provide expert consulting support for drug discovery, clinical research, and regulatory submissions.

Makya is a user-friendly SaaS-based platform for AI-driven drug design focusing on Multi-Parametric Optimization. It allows the design of novel compounds that are easy to make in accordance with a multiobjective blueprint at unprecedented speeds, performance and diversity. Makya has multiple generative algorithms that cover different use cases, from hit discovery to lead optimizing: fine-tuning to find optimal solutions in your chemical space according to your project blueprint; novelty to find new ideas of high novelty for rescaffolding/hit discoveries; forward to design a focused collection of compounds easily accessible using commercial starting materials. The new Makya 3D Module enhances the user-experience and scientific utility of Makya. Makya 3D offers a wide range of 3D modeling capabilities in both ligand and structure-based pipelines. You can now use these 3D scores to guide generation natively within Makya.

A series of carefully planned experiments can help you discover biological biomarkers, uncover disease mechanisms, find new drugs, or identify protein levels changes. It's easy to unlock the power of MS/Proteomics. This allows you to focus on the biological complexity and get closer to the moment for discovery. Our automated, repeatable workflow makes it easier to start experiments and reduce turnaround times. This gives you the flexibility and control to make decisions and act on them immediately. Our proteomics data processing workflow allows you to concentrate on biological insights and human to human collaboration. It is built to scale repeatedly. We have made repetitive and heavy processing easy to use the cloud, making it a seamless and enjoyable experience. Intelligent Proteomics seamlessly integrates complex moving parts to allow larger experiments to be processed, analyzed, and reported with ease.

CDD Vault allows you to intuitively organize chemical structures, biological study data, as well as collaborate with external or internal partners via a simple web interface. Start a free trial to see how easy it can be to manage drug discovery data. Tailored for You Affordable Scales with your project team Activity & Registration * Electronic Lab Notebook * Visualization * Inventory * APIs

ArgusLab is a program that allows you to molecular model, graphically, and design drugs for Windows operating systems. Although it is becoming a little outdated, it remains very popular. There have been more than 20,000 downloads to date. ArgusLab can be downloaded for free. You don't have to sign anything. If you're teaching a class in which ArgusLab might be useful, you can print as many copies as necessary. You cannot redistribute ArgusLab to other websites or sources. You may link to this website on your own websites, however. ArgusLab is being port to the iPad in a low-key effort. I have also worked with Qt cross-platform development environment to support Mac, Linux, and PC.

Automated surveillance of any source of data, fully integrated with a GVP IX-compliant signal management platform. GVP-IX compliant signal-management platform integrated into Evidex and ready-to-use off-the-shelf. Modernize and audit-proof all your management processes without the need to switch between platforms or services. Your safety data is worth more than you think. Automating signal detection and management allows you to focus on your organization's value, not just regulatory requirements. Safety signals can be identified from traditional sources such as ICSR databases, FDA Adverse Events Reporting System (FAERS), VigiBase, and clinical trial data. Incorporate new data sources like claims, EHR, or other unstructured data. These data sources can be combined seamlessly to improve signaling algorithms, increase validations and assessment efficiency, and provide faster answers for drug safety questions.

NoviSight 3D Cell Analysis Software advances your discovery by providing statistical information for spheroids, and other 3D objects in microplate based experiments. It allows you to quantify cell activity in three dimensions, capture rare events more easily, increase detection sensitivity, and obtain accurate cell counts. NoviSight software has a simple user interface that allows you to perform analysis, recognition, and statistical analyses. NoviSight software's True 3D technology allows you to easily check the morphology and size of your samples. To speed up your research, measure a variety of cell nuclei parameters such as volume and sphericity. You can also analyze 3D cell models that are physiologically relevant to your work. The software can be used to analyze objects of interest and provide spatiotemporal and morphological information in 3D space. You can detect objects from whole structures to subcellular details and analyze changes in spheroids.

Discngine Assay, a laboratory informatics tool, integrates all phases of plate-based tests into a coherent, compliant and efficient workflow. It is an essential tool for research labs that screen. It allows scientists to streamline their entire High Throughput screening workflow, from sample analysis and assay data storage to data warehousing to liquid handling equipment qualification. Discngine Assay's intuitive interface and robust API integrate seamlessly with Lab equipments, existing IT environments, and ensure efficient data capture and analysis. It is designed to accelerate the discovery of new molecules, while also addressing the needs of the pharmaceutical, biotech and CRO industries. This will enhance collaboration and drive innovation in life sciences research.

Deliver personalized patient care using the only objective, quantitative, and histologically validated arterial analysis software based on CTA. Use ground-truth histology in order to visualize the cause of myocardial ischaemia and to inform heart attack and stroke risks. Undiagnosed, untreated non-obstructive but unstable plaques in the arteries are the primary cause of heart attack and stroke. Current non-invasive tests cannot visualize the biology deep within artery walls, where heart disease develops. Elucid uses artificial intelligence and scientific imaging to provide noninvasive, quick diagnoses of cardiovascular disease and precise treatment. This will improve patient outcomes. Assess plaque composition using histology-validated computer software. With greater accuracy, quantify heart attack and stroke risks. Visualize a comprehensive, objective view of arterial diseases to enable personalized treatment before a patient enters the hospital.

R&D and manufacturing labs must be able to change and reconfigure on the fly in order to accelerate new discoveries and bring products to market quickly. Data management shouldn't be a problem. Thermo Scientific™, Nautilus LIMS™, for Dynamic Discovery and R&D Environments was developed in partnership with customers. It is highly configurable and flexible. It increases workflow efficiency, throughput, data reliability, and simplifies administration, sample traceability, and regulatory compliance.

RetinAI's software discovery platform is used by healthcare professionals and pharmaceutical companies to manage their data and gain enhanced insights through automatic AI analysis. It also supercharges clinical and research workflows. A single data platform that allows you to access and manage your data from anywhere at any time. Compatible formats include DICOM compliant and proprietary formats. AI is used to harmonize, organize, aggregate & analyze data at scale in order to extract insights into disease progression, treatment outcome & progression prediction. Secure cloud-based data access allows for collaborative research across your organization. The central hub for data, digital, and medical teams. Perform AI-based analyses on your OCT volume for layer and fluid segmentation. Centralize your insights and provide immediate evaluation in a single platform. Invite collaborators instantly to access and work on datasets with different levels of permission.

Accuracy, speed, confidence. Introduce generative AI in commercial biopharma. Simplify the laborious process of collecting, organizing and inspecting vast quantities of complex data. You can always rely on 100% accuracy to get the insights you need. You'll never again lose track of your workflows with our AI-powered data verification and manipulation platform. All in one place, you can gather, refine and check all your data. Search public and private databases based on key drug characteristics. Segment drugs and clinical trials based on detailed patient profiles. You can extract the data in plain English. Link your answers to their original source. Spend your time and effort on synthesising high-quality outputs rather than sifting through data. Our LLMs allow researchers to scan assets 4.8x faster by hand. We index more than 38M scientific publications and abstracts from conferences, clinical trials, and other sources. All the data that you need, at the time you need it.

Our platform is regulatory compliant and allows clinical research to be done by analyzing unstructured EMR data in order to identify life-threatening conditions. We develop technologies that increase access to the most innovative healthcare through clinical trials. Our team is focused on saving lives and providing access to new healthcare therapeutic innovations that are still being investigated. We believe every patient should be informed about their options to participate in clinical trials that could offer therapies that significantly save or improve their lives. We are an AI-based healthcare research company that has developed a platform that uses computational technology to identify patients who meet a complex set criteria and allows them to participate in clinical trials.

Our global data-sharing networks generate clinically actionable insights to improve patient outcomes globally. SOPHiA GENETICS is on a mission to build the future in AI-assisted medical care. We are integrating multimodal data from healthcare-omics, unlocking existing data silos and developing machine learning models in order to produce actionable insight that can eventually support healthcare professionals improve patient outcomes. The new interface, features, and cutting edge capabilities will accelerate precision medicine workflows and bring us closer to democratizing the data-driven medicine.

Our AI-driven technology transforms healthcare data from both structured and unstructured into a reliable, high-quality, standard dataset that can be used throughout your organization. It is the industry's best. Our products and services allow you to access data in near real time from disparate systems. This allows your administrative and clinical team to reclaim that time for quality and research. Our products and services can be used to collect, analyze and act on data regardless of its source, therapeutic area, organization department, or existing reporting or BI tools. Atlas combines human expertise with the power of AI to automate the time-consuming task of finding and understanding patient data for clinical registers. Cartographer analyzes, interprets, and interprets patient information across all platforms. He also standardizes the data and makes data recommendations.

EVIDENS, our AI platform, enables digital cohort discovery and research. It also allows collaboration and insight sharing on large hospital-wide data sets. Quickly annotate your data and link it into AI-ready data collections. You can quickly filter populations based upon demographics or clinical outcomes. You can filter populations using unlimited keywords by training AI models that can search with them. Smart AI assistance can help you identify potential cohorts by creating criteria and exploring them. Rapidly train AI models to automate analysis, and group data. To test your clinical hypothesis, you can create AI-ready cohorts. View the status and tasks of all your projects and collaborators easily. You can view and follow activity that is related to your research interests. Collaborative tools are available to help you create, train, and validate AI models.

Geneious Prime makes bioinformatics more accessible by transforming raw information into visualizations which make sequence analysis intuitive. Simple assembly of sequences and easy editing contigs. Automatic annotation of gene prediction, motifs and translation. Genotype microsatellite trace with automated ladder fitting, peak calling, and generation of tables of alleles. A highly customizable sequence view displays beautiful visualizations of annotated assemblies and genomes. SNP variants analysis with powerful SNPs, RNA-Seq analysis and amplicon metagenomics. Create your own searchable database of primers for PCR and sequencing and design and test them. Geneious Biologics offers a flexible, scalable and secure way to streamline antibody analysis workflows. It allows you to create high-quality libraries, and select the best therapeutic candidates.

Cortellis™, a suite of life science intelligence software solutions, reveals hidden insights in data. This allows you to make better informed decisions throughout the R&D process. We have taken out the tedious work of finding, integrating and analysing data so that you can concentrate on the crucial decisions required to bring your products to market quicker. Cortellis provides unique data analysis that is rich in domain knowledge, industry insight, and therapeutic expertise. This allows you to unlock hidden insights that will allow you to make data-driven decisions that drive innovation. With the most comprehensive and deepest intelligence, you can get precise and actionable answers to specific questions throughout the R&D process. Cortellis is an indispensable part your daily work flow.